Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.

Abstract excerpt

Lung cancer has traditionally been classified by histology. However, a greater understanding of disease biology and the identification of oncogenic driver alterations has dramatically altered the therapeutic landscape. Consequently, the new classification paradigm of non-small-cell lung cancer is further characterized by molecularly defined subsets actionable with targeted therapies and the treatment landscape is...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Resistance, Neoplasm
• Share to Gene Rearrangement